E.g., 24/09/2020
E.g., 24/09/2020

First-Half 2020 Results

02 September, 2020

  • Organic sales growth of 15.7% in first-half 2020:
    • €1,476 million in sales
    • Up 15.8% as reported
  • As expected, a mixed sales performance, with faster momentum in molecular biology solutions contrasting with...

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

16 July, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, has announced the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.),...

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 July, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) is CE marked. The BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) tests for 23...

Second-Quarter 2020 Business Performance Preannouncement

09 July, 2020

In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.

  • Organic growth of 15.7...

bioMérieux issues a €200 million Euro PP bond  

29 June, 2020

Marcy l’Étoile (France) - June 29, 2020 – bioMérieux, a global leader in the field of in vitro diagnostics, announces that it has successfully issued today a €200 million Euro PP new debt with a top-tier European institutional...

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

21 May, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect...

Information concerning 2019 dividend and the bioMérieux  General Shareholders’ Meeting 

19 May, 2020

The Board of Directors of bioMérieux met today and decided to hold the annual General Shareholders’ Meeting behind closed doors at the bioMérieux registered office on June 30, 2020. During this meeting, it will recommend reducing the 2019 dividend in order to support initiatives in the...

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch  

06 May, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV...

BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization 

04 May, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in syndromic infectious disease testing, has received Emergency Use Authorization by the U.S. Food and Drug Administration...

First-Quarter 2020 Business Review

16 April, 2020

  • bioMérieux fully mobilized against COVID-19 epidemic
  • Organic growth of more than 20% at constant exchange rates and scope of consolidation over the first quarter:
    • €769 million in sales
    • Up 21.5% as reported
    ...